Medifast (MED) Tops Q2 EPS by 65c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts MED Hot Sheet
Price: $11.87 -2.47%
EPS Growth %: -195.2%
Financial Fact:
Cost of sales: 16.42M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -195.2%
Financial Fact:
Cost of sales: 16.42M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Medifast (NYSE: MED) reported Q2 EPS of $3.96, $0.65 better than the analyst estimate of $3.31. Revenue for the quarter came in at $394.2 million versus the consensus estimate of $358.45 million.
GUIDANCE:
Medifast sees Q3 2021 EPS of $12.70-$14.17, versus the consensus of $13.80. Medifast sees Q3 2021 revenue of $1.425-1.525 million, versus the consensus of $1.46 million.
For earnings history and earnings-related data on Medifast (MED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Infosys Limited (INFY) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
